Moderna Turns First Profit, Boosted by Its Covid-19 Vaccine

Moderna Turns First Profit, Boosted by Its Covid-19 Vaccine

The vaccine brought Moderna revenue of $1.73 billion in the first quarter, but the prospect of a temporary loss of vaccine patents clouds investors’ outlook.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting